<DOC>
	<DOCNO>NCT00628576</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety new acute treatment deep venous thrombosis use low-molecular-weight heparin compare standard treatment use unfractionated heparin , especially concern long-term morbidity .</brief_summary>
	<brief_title>Evaluation Long-Term Sequelae After Thrombophlebitis , i.e . Deep Venous Thrombosis Lower Extremities</brief_title>
	<detailed_description>Deep-venous thrombosis ( DVT ) remain common clinical problem ( annual incidence 0.10-0.16 % ) long-term morbidity chronic venous insufficience ( CVI ) 10-30 % . As recurrent DVT , initial treatment Low-Molecular-Weight Heparin ( to-day 's terminology Fractionated Heparin ( FH ) ) Unfractionated Heparin ( UFH ) show equal efficiency , whereas efficacy concern long-term morbidity recently publish . This study initiate compare efficacy UFH FH concern incidence CVI symptomatic DVT short-term long-term follow-up .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<criteria>First DVT without know risk factor except overt cancer Second DVT two year first patient without clinical sign CVI . Contraindication anticoagulation therapy Candidate thrombectomy arteriousvenous fistula thrombolytic therapy Known cancer time DVT diagnosis Patients unable cooperate anticoagulation therapy manage test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Deep Venous Thrombosis</keyword>
	<keyword>low extremity</keyword>
	<keyword>Chronic Venous Insufficiency</keyword>
	<keyword>Postthrombotic Syndrome</keyword>
	<keyword>Heparins</keyword>
	<keyword>Low-molecular- weight heparin</keyword>
	<keyword>Tinzaparin</keyword>
</DOC>